Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
Identifieur interne : 001B79 ( PubMed/Curation ); précédent : 001B78; suivant : 001B80Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
Auteurs : E C Wolters [Canada] ; T A Hurwitz ; E. Mak ; P. Teal ; F R Peppard ; R. Remick ; S. Calne ; D B CalneSource :
- Neurology [ 0028-3878 ] ; 1990.
English descriptors
- KwdEn :
- Aged, Aged, 80 and over, Clozapine (therapeutic use), Dibenzazepines (therapeutic use), Dopamine Agents (adverse effects), Double-Blind Method, Female, Humans, Male, Middle Aged, Parkinson Disease (drug therapy), Parkinson Disease (psychology), Psychiatric Status Rating Scales, Psychoses, Substance-Induced (etiology), Psychoses, Substance-Induced (prevention & control), Randomized Controlled Trials as Topic, Sleep (drug effects).
- MESH :
- chemical , adverse effects : Dopamine Agents.
- chemical , therapeutic use : Clozapine, Dibenzazepines.
- drug effects : Sleep.
- drug therapy : Parkinson Disease.
- etiology : Psychoses, Substance-Induced.
- prevention & control : Psychoses, Substance-Induced.
- psychology : Parkinson Disease.
- Aged, Aged, 80 and over, Double-Blind Method, Female, Humans, Male, Middle Aged, Psychiatric Status Rating Scales, Randomized Controlled Trials as Topic.
Abstract
In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of the 6 patients. In the dosage used, clozapine's usefulness was limited by its propensity to produce sedation, confusion, and increased parkinsonism.
PubMed: 1970427
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001B79
Links to Exploration step
pubmed:1970427Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.</title><author><name sortKey="Wolters, E C" sort="Wolters, E C" uniqKey="Wolters E" first="E C" last="Wolters">E C Wolters</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University Hospital, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University Hospital, University of British Columbia, Vancouver</wicri:regionArea></affiliation></author><author><name sortKey="Hurwitz, T A" sort="Hurwitz, T A" uniqKey="Hurwitz T" first="T A" last="Hurwitz">T A Hurwitz</name></author><author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E" last="Mak">E. Mak</name></author><author><name sortKey="Teal, P" sort="Teal, P" uniqKey="Teal P" first="P" last="Teal">P. Teal</name></author><author><name sortKey="Peppard, F R" sort="Peppard, F R" uniqKey="Peppard F" first="F R" last="Peppard">F R Peppard</name></author><author><name sortKey="Remick, R" sort="Remick, R" uniqKey="Remick R" first="R" last="Remick">R. Remick</name></author><author><name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S" last="Calne">S. Calne</name></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="1990">1990</date><idno type="RBID">pubmed:1970427</idno><idno type="pmid">1970427</idno><idno type="wicri:Area/PubMed/Corpus">001B79</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001B79</idno><idno type="wicri:Area/PubMed/Curation">001B79</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001B79</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.</title><author><name sortKey="Wolters, E C" sort="Wolters, E C" uniqKey="Wolters E" first="E C" last="Wolters">E C Wolters</name><affiliation wicri:level="1"><nlm:affiliation>Department of Medicine, University Hospital, University of British Columbia, Vancouver, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Department of Medicine, University Hospital, University of British Columbia, Vancouver</wicri:regionArea></affiliation></author><author><name sortKey="Hurwitz, T A" sort="Hurwitz, T A" uniqKey="Hurwitz T" first="T A" last="Hurwitz">T A Hurwitz</name></author><author><name sortKey="Mak, E" sort="Mak, E" uniqKey="Mak E" first="E" last="Mak">E. Mak</name></author><author><name sortKey="Teal, P" sort="Teal, P" uniqKey="Teal P" first="P" last="Teal">P. Teal</name></author><author><name sortKey="Peppard, F R" sort="Peppard, F R" uniqKey="Peppard F" first="F R" last="Peppard">F R Peppard</name></author><author><name sortKey="Remick, R" sort="Remick, R" uniqKey="Remick R" first="R" last="Remick">R. Remick</name></author><author><name sortKey="Calne, S" sort="Calne, S" uniqKey="Calne S" first="S" last="Calne">S. Calne</name></author><author><name sortKey="Calne, D B" sort="Calne, D B" uniqKey="Calne D" first="D B" last="Calne">D B Calne</name></author></analytic><series><title level="j">Neurology</title><idno type="ISSN">0028-3878</idno><imprint><date when="1990" type="published">1990</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Clozapine (therapeutic use)</term><term>Dibenzazepines (therapeutic use)</term><term>Dopamine Agents (adverse effects)</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Psychiatric Status Rating Scales</term><term>Psychoses, Substance-Induced (etiology)</term><term>Psychoses, Substance-Induced (prevention & control)</term><term>Randomized Controlled Trials as Topic</term><term>Sleep (drug effects)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Clozapine</term><term>Dibenzazepines</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Sleep</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Psychoses, Substance-Induced</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Aged, 80 and over</term><term>Double-Blind Method</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Psychiatric Status Rating Scales</term><term>Randomized Controlled Trials as Topic</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of the 6 patients. In the dosage used, clozapine's usefulness was limited by its propensity to produce sedation, confusion, and increased parkinsonism.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">1970427</PMID><DateCreated><Year>1990</Year><Month>05</Month><Day>31</Day></DateCreated><DateCompleted><Year>1990</Year><Month>05</Month><Day>31</Day></DateCompleted><DateRevised><Year>2013</Year><Month>11</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0028-3878</ISSN><JournalIssue CitedMedium="Print"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>1990</Year><Month>May</Month></PubDate></JournalIssue><Title>Neurology</Title><ISOAbbreviation>Neurology</ISOAbbreviation></Journal><ArticleTitle>Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.</ArticleTitle><Pagination><MedlinePgn>832-4</MedlinePgn></Pagination><Abstract><AbstractText>In a double-blind placebo-controlled study, we evaluated the effects of clozapine (75 to 250 mg/day, mean 170.8) on dopaminomimetic psychosis and parkinsonian disability. Clozapine prevented deterioration of psychosis during the increase of dopaminomimetics in the 3 patients who completed the study. Worsening of parkinsonism occurred in 3 of the 6 patients. In the dosage used, clozapine's usefulness was limited by its propensity to produce sedation, confusion, and increased parkinsonism.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wolters</LastName><ForeName>E C</ForeName><Initials>EC</Initials><AffiliationInfo><Affiliation>Department of Medicine, University Hospital, University of British Columbia, Vancouver, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurwitz</LastName><ForeName>T A</ForeName><Initials>TA</Initials></Author><Author ValidYN="Y"><LastName>Mak</LastName><ForeName>E</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Teal</LastName><ForeName>P</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Peppard</LastName><ForeName>F R</ForeName><Initials>FR</Initials></Author><Author ValidYN="Y"><LastName>Remick</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Calne</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Calne</LastName><ForeName>D B</ForeName><Initials>DB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurology</MedlineTA><NlmUniqueID>0401060</NlmUniqueID><ISSNLinking>0028-3878</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D003984">Dibenzazepines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015259">Dopamine Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>J60AR2IKIC</RegistryNumber><NameOfSubstance UI="D003024">Clozapine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003024" MajorTopicYN="N">Clozapine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003984" MajorTopicYN="N">Dibenzazepines</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015259" MajorTopicYN="N">Dopamine Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011569" MajorTopicYN="N">Psychiatric Status Rating Scales</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011605" MajorTopicYN="N">Psychoses, Substance-Induced</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012890" MajorTopicYN="N">Sleep</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>1990</Year><Month>5</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>1990</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>1990</Year><Month>5</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">1970427</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B79 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 001B79 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:1970427
|texte= Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:1970427" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |